IRRISEPT® Introduces New Senior Manager, Clinical Affairs

ATLANTA, June 6, 2014 /PRNewswire/ -- IrriMax Corporation is proud to announce the appointment of Peter Graves, BSN, RN, CNOR as Senior Manager, Clinical Affairs for innovative product IRRISEPT, the first and only FDA-cleared cleansing and debridement system containing 0.05% Chlorhexidine Gluconate (CHG) for irrigation.

"The company is growing very quickly and we believe the addition of key clinical personnel is crucial," said CEO, Gareth Clarke.  "Peter will be an integral part of our growing clinical team.  He brings the experience necessary and the important relationships in the surgical arena, to help us be successful."

The company's main corporate goal is to help treat and prevent infections, help improve patient outcomes and drive positive impact to healthcare economics regarding surgical infections.  As it moves forward with a large scale clinical trial, IrriMax continues to expand its resources and drive to their goal of becoming 'Standard of Care'.

Carolyn Twomey, VP, Clinical Affairs stated, "The addition of a high caliber candidate like Peter continues to elevate the expertise, credibility, and character of the clinical team."  She went on to say, "We are getting ready to launch a multi-center, randomized, controlled, clinical trial with IRRISEPT.  Corporately, we are driving a rigorous, world-class clinical program and it's imperative to have the right people in place."

Additionally, IrriMax, with NAMSA Labs, has recently completed two in-vivo animal studies on IRRISEPT addressing Acute Systemic Toxicity and Systemic and Neurological Toxicity.  These studies demonstrate IRRISEPT shows no systemic toxicity or significant local effects.  Final reports are on file and available upon request. 

The IrriMax clinical team invites APIC members to visit IRRISEPT in Booth #626 to discuss the new study findings and meet our newest clinical team member, Peter Graves. 

IRRIMAX CORPORATION
IrriMax ^® Corporation develops and markets cleansing, debridement and irrigation solutions using a patented, innovative delivery method. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information visit www.irrisept.com.

CONTACT
Kelly Herman
IrriMax Corporation
Corporate Headquarters  770-807-3355
[email protected]

SOURCE IrriMax Corporation